Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLRX POWR Grades
- SLRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 68.43% of US stocks.
- SLRX's strongest trending metric is Value; it's been moving down over the last 76 days.
- SLRX's current lowest rank is in the Momentum metric (where it is better than 4.14% of US stocks).
SLRX Stock Summary
- The ratio of debt to operating expenses for Salarius Pharmaceuticals Inc is higher than it is for about merely 0.5% of US stocks.
- With a year-over-year growth in debt of -100%, Salarius Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
- Revenue growth over the past 12 months for Salarius Pharmaceuticals Inc comes in at -64.84%, a number that bests only 2.24% of the US stocks we're tracking.
- Stocks that are quantitatively similar to SLRX, based on their financial statements, market capitalization, and price volatility, are SLS, MNDO, PULM, SINT, and PZG.
- Visit SLRX's SEC page to see the company's official filings. To visit the company's web site, go to www.salariuspharma.com.
SLRX Valuation Summary
- SLRX's price/sales ratio is 9.9; this is 12.78% lower than that of the median Healthcare stock.
- SLRX's price/sales ratio has moved NA NA over the prior 80 months.
- SLRX's price/sales ratio has moved NA NA over the prior 80 months.
Below are key valuation metrics over time for SLRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SLRX | 2021-08-31 | 9.9 | 1.0 | -5.3 | -1.6 |
| SLRX | 2021-08-30 | 9.5 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-27 | 9.5 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-26 | 9.6 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-25 | 9.5 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-24 | 9.0 | 0.9 | -4.8 | -1.1 |
SLRX Growth Metrics
- Its 5 year cash and equivalents growth rate is now at -82.18%.
- The 3 year price growth rate now stands at -95.19%.
- The 2 year cash and equivalents growth rate now stands at -56.3%.
The table below shows SLRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 1.840216 | -10.2002 | -12.76824 |
| 2021-09-30 | 3.319138 | -8.853078 | -10.82732 |
| 2021-06-30 | 4.697377 | -10.02412 | -8.806852 |
| 2021-03-31 | 5.3693 | -9.326119 | -7.516741 |
| 2020-12-31 | 5.233301 | -10.31136 | -7.748661 |
| 2020-09-30 | 4.793072 | -11.57444 | -7.467527 |
SLRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SLRX has a Quality Grade of D, ranking ahead of 5.25% of graded US stocks.
- SLRX's asset turnover comes in at 0.129 -- ranking 239th of 682 Pharmaceutical Products stocks.
- XTNT, CPRX, and BMY are the stocks whose asset turnover ratios are most correlated with SLRX.
The table below shows SLRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.129 | 1.000 | -2.587 |
| 2021-03-31 | 0.183 | 1.000 | -2.888 |
| 2020-12-31 | 0.242 | 1.000 | -4.816 |
| 2020-09-30 | 0.254 | 1.000 | -15.428 |
| 2020-06-30 | 0.256 | 1.000 | 9.857 |
| 2020-03-31 | 0.231 | 0.989 | 6.965 |
SLRX Price Target
For more insight on analysts targets of SLRX, see our SLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.43 | Average Broker Recommendation | 1.33 (Strong Buy) |
SLRX Stock Price Chart Interactive Chart >
SLRX Price/Volume Stats
| Current price | $0.21 | 52-week high | $1.20 |
| Prev. close | $0.21 | 52-week low | $0.16 |
| Day low | $0.20 | Volume | 1,188,800 |
| Day high | $0.23 | Avg. volume | 802,692 |
| 50-day MA | $0.20 | Dividend yield | N/A |
| 200-day MA | $0.51 | Market Cap | 11.93M |
Salarius Pharmaceuticals Inc (SLRX) Company Bio
Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.
Latest SLRX News From Around the Web
Below are the latest news stories about Salarius Pharmaceuticals Inc that investors may wish to consider to help them evaluate SLRX as an investment opportunity.
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual ConferenceHOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will present during the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference on Thursday, February 24, 2022. During the presentation, Mr. Arthur will highlight Salarius’ busi |
Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five |
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor ConferenceHOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will deliver a virtual presentation at the 2022 BIO CEO & Investor Conference. The event is taking place February 14-17, 2022, at the New York Marriott Marquis as a hybrid conference that allows vir |
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation ProgramDr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assetsHOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company’s new targeted protein degradation program. In this newly created position, Dr |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayHappy Friday, trader! |
SLRX Price Returns
| 1-mo | 13.57% |
| 3-mo | -49.47% |
| 6-mo | -59.57% |
| 1-year | -80.56% |
| 3-year | -98.42% |
| 5-year | -99.78% |
| YTD | -57.63% |
| 2021 | -45.54% |
| 2020 | -75.93% |
| 2019 | -54.18% |
| 2018 | -90.54% |
| 2017 | -33.90% |
Loading social stream, please wait...